Clinical Trials
2
Active:0
Completed:0
Trial Phases
2 Phases
Phase 1:1
Phase 3:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (50.0%)Phase 3
1 (50.0%)AB1 in Adult Patients with Sickle Cell Disease (SCD)
- First Posted Date
- 2022-03-02
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Nirmish Shah
- Target Recruit Count
- 16
- Registration Number
- NCT05261711
- Locations
- 🇺🇸
Augusta University Medical Center, Augusta, Georgia, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
🇺🇸East Carolina University, Greenville, North Carolina, United States
Apixaban in Patients With Sickle Cell Disease
Phase 3
Terminated
- Conditions
- Sickle Cell DiseaseVaso-occlusive CrisisReduction in Hospitalizations
- Interventions
- Drug: Placebo
- First Posted Date
- 2014-07-01
- Last Posted Date
- 2020-03-11
- Lead Sponsor
- Nirmish Shah
- Target Recruit Count
- 16
- Registration Number
- NCT02179177
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
News
No news found